Alcon to acquire approved ophthalmic drugs

Alcon Inc. (NYSE:ACL) will acquire exclusive, U.S. rights to two approved ophthalmic drugs from Sirion Therapeutics Inc. (Tampa, Fla.): Zirgan ganciclovir ophthalmic gel and Durezol difluprednate. Zirgan was approved in the U.S. in September to treat acute herpetic keratitis. Alcon expects the antiviral gel that targets viral DNA to be available in the U.S. this year. Durezol, a topical ophthalmic emulsion containing difluprednate, is marketed to treat postoperative ocular inflammation and pain. ...